Opus Genetics (STU:R3X1) Buyback Yield % : -11.14 (As of Apr. 28, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Opus Genetics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Opus Genetics's current buyback yield was -11.14%.

Opus Genetics Buyback Yield % Historical Data

The historical data trend for Opus Genetics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opus Genetics Buyback Yield % Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-43.16

-6.92

-13.00

-12.38

Opus Genetics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-12.78	-4.83	-10.06	-12.98	-11.76

Competitive Comparison of Opus Genetics's Buyback Yield %

For the Biotechnology subindustry, Opus Genetics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opus Genetics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opus Genetics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Opus Genetics's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Opus Genetics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Opus Genetics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (-0.075	+	4.295)	/	34.101
	=	-12.38%

Opus Genetics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (-0.075	+	4.295)		/	34.101
	=	-12.38%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Opus Genetics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Opus Genetics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Opus Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opus Genetics Inc (STU:R3X1) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

IRD:USA R3X1:Germany

Address

8 Davis Drive, Suite 220, Durham, NC, USA, 27709

Website

https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Opus Genetics Headlines

No Headlines